Combined therapy VS only levodopa therapy in a 5-years follow up cohort
Objective: Describe the frequencies of appearance of motor fluctuations, impulse control disorders, in two therapeutic regimes: combined therapy (levodopa plus an other antiparkinsonian drug) or…Effect of the MAO-B inhibitor and glutamate modulator safinamide on depressive symptoms in three Parkinson’s disease patients
Objective: Patients suffering from Parkinson’s disease experience various motor and non-motor symptoms. Within the range of non-motor symptoms depression is reported as high as in…Accounting for unmeasured confounders in treatment response: a comparison of levodopa versus non-levodopa dopaminergic drugs
Objective: To compare short-term levodopa and non-levodopa dopaminergic treatment response in people with Parkinson’s disease (PD) using instrumental variable analysis and linear regression. Background: Treatment…Safinamide improves motor symptoms severity and daily living in Parkinson’s Disease (PD) patients
Objective: To evaluate the clinical effects of safinamide, administered as add-on therapy to levodopa in fluctuating PD patients, on symptoms severity and daily living. Background:…Opicapone added to safinamide in patients affected by Parkinson’s disease for better controlling motor fluctuations
Objective: The aim of this clinical observation was to verify the sparing of levodopa in patients affected by Parkinson's disease who already started safinamide treatment for…Safinamide: real world evidence in Toledo´s Movement Disorders Unit
Objective: We present a prospective observational-real life study about the use of safinamide in Movement Disorders Unit´s patients. Background: The gold standard of pharmacological treatment…Addition of Opicapone to Safinamide in Parkinson’s Disease patients
Objective: To assess safety and efficacy of Opicapone in patients treated with Levodopa and Safinamide presenting early morning “off” states and akinesia. Background: Safinamide is…SAFINAMIDE IN DAILY CLINICAL PRACTICE: ASSESSMENT OF EFFICACY AND TOLERABILITY IN PARKINSON´S DISEASE
Objective: to analyze the long term efficacy and tolerability of safinamide added as adjunctive therapy in a series of patients with Parkinson´s disease (PD) Background:…Evolution of anti-parkinsonian drug prescribing patterns in Parkinson’s disease
Objective: To compare Parkinson’s disease (PD) treatment practices by movement disorder (MD) specialists across a decade, and to determine the factors that influence drug choice…Effects of safinamide and rasagiline on in vivo glutamate release in 6-OHDA hemilesioned rats
Objective: To investigate the effects of safinamide (saf) and rasagiline on in vivo glutamate (Glu) release in the 6-hydroxydopamine (6-OHDA) hemilesioned rat model of Parkinson’s…
Abstracts from the International Congress of Parkinson’s and Movement Disorders.